Shanghai Fosun Pharmaceutical's subsidiary, which holds a majority stake, has obtained drug registration approval for Hydroxylamine Tartarate Injection.

Shanghai Fosun Pharmaceutical (02196) announced that its controlling subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has recently obtained approval from the National Medical Products Administration for the market registration application of its oxymetazoline hydrochloride injection. This drug is a chemical drug independently developed by the group (including the company and its controlling subsidiaries/units). It is mainly used for (1) treating acute hypotension during epidural anesthesia; (2) as an adjunctive symptomatic treatment for hypotension caused by bleeding, drug allergies, surgical complications, and shock due to head trauma or brain tumors; and (3) hypotension caused by cardiogenic shock or sepsis. As of December 2024, the group has invested approximately RMB 8.56 million (unaudited) in research and development for this drug. According to the latest data from IQVIA CHPA, the sales revenue of oxymetazoline hydrochloride injection in China (excluding the Hong Kong, Macau, and Taiwan regions) was approximately RMB 1.579 billion in 2023. The approval of this drug for marketing will further enrich the group's product line. It is expected that the approval will not have a significant impact on the group's current performance.